Side-by-side · Research reference

ProstamaxvsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/38 cited

BHuman-MechanisticAUTO-DRAFTED12/40 cited

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

Prostamax

Thymalin

Primary target

Chromatin in prostatic cells — pericentromeric heterochromatin regions

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

—

Origin

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

—

02Dosage Protocols

Parameter

Prostamax

Thymalin

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

—

Human clinical dose

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

—

Evidence basis

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Russian clinical + in vitroKhavinson 2002

Age groups studied

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

—

Duration

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

5–10 day cycles, 1–2× per year

Standard dose

—

5–10 mg / day IM × 5–10 daysKhavinson 2002

Frequency

—

Once daily during cycle

Lower / starter dose

—

2.5 mg / day

Reconstitution

—

Saline or bacteriostatic water

Timing

—

Morning preferred

Half-life

—

Hours (estimated)

04Side Effects & Safety

Parameter

Prostamax

Thymalin

Published adverse events

None reported in available literature

—

Genotoxicity signals

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

—

Metal ion interactions

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

—

Human safety data

Absent — no published Phase 1/2/3 trials

—

Injection site reaction

—

Mild erythema at IM site

Allergic reaction

—

Rare hypersensitivity to bovine-derived polypeptide

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

Prostamax

Thymalin

1. Route

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Reconstitution

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

Intramuscular — deltoid or gluteal. Rotate sites.

3. Frequency

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

Morning preferred during cycle.

4. Monitoring

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Note

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

23–25G, 25–38 mm IM needle.

06Stack Synergy

Prostamax

— no documented stacks

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001